LifeMD, Inc.
LifeMD, Inc. (LFMDP): 2 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.2 months
D/E 3.66 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for LifeMD, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.1B
Cash
$34.5M
Quarterly Burn
$53.2M
Runway
2.2 mo
Revenue
$50.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| bupropion | Approved |
| glp-1 medications | Approved |
Frequently asked questions
How many drug candidates are in LifeMD, Inc.'s pipeline?
LifeMD, Inc. (LFMDP) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LifeMD, Inc.'s lead drug candidate?
LifeMD, Inc.'s most advanced tracked candidate is bupropion (Approved) for Weight management.
What is LifeMD, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LifeMD, Inc. has approximately 2.2 months of cash runway.
What is LifeMD, Inc.'s market capitalization?
LifeMD, Inc.'s market capitalization is approximately $1.1B.
Who is the CEO of LifeMD, Inc.?
Mr. Justin Schreiber is the chief executive officer of LifeMD, Inc. (LFMDP).
Get the full picture on LifeMD, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.